|
|
Fierce Competition for a Shrinking HCV MarketPublished by: BioSeeker Group AB Published: Oct. 21, 2002 - 55 Pages Table of ContentsExecutive Summary
AbstractHepatitis C virus (HCV) has already caused a global epidemic, but the worst may yet be to come. According to the CDC nearly 4 million people are or have been infected with HCV in the U.S. alone. Of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade.The number of new infections per year, however, has declined from an average of 240,000 in the 1980s to about 25,000 in 2001. By 2020 almost all of the infected will have had the disease for more than 25 years. Between the years 2010 and 2020, most patients will then have reached an age of 55 to 75 years, many infected will die of other reasons before they will be diagnosed and started any anti-HCV therapy. In this Highlight Report, BioSeeker has focused on three classes of therapeutic approaches as they represent different therapeutic strategies, but also as they target different time spans in the HCV market: immunomodulating substances, protease inhibitors, and vaccines. There is still a strong interest in developing new immunomodulating therapies for HCV despite the promise of the pegylated interferons. There is also increasing enthusiasm for targeting HCV molecular products such as protease inhibitors. The understanding of hepatitis C at a molecular level has also opened the door for more targeted development of a prophylactic or therapeutic HCV vaccine. The report analyzes the short, mid-range and long-term market development by studying three different therapeutic approaches in different developmental stages. Several large pharmaceutical companies are conducting R&D related to HCV, but with different focus. BioSeeker Group tries to assess the competition between these therapeutic strategies and to correlate this with possible market development. Due to the high competition and a shrinking market some therapies will have difficulties to reach sufficient revenues within their lifecycle. Activities from a total of 50 companies are described. Our Highlight Reports are produced to enable our customers to be updated on the progress within different sectors of the biotechnology industry, and will give you access to achievements and novel breakthroughs during the latest years of activities. Apart from the pharma industry itself, this report is of value to investors, science incubators, investigators, contract research organizations or any other types of organization that have an interest in new antifungal therapies. Companies included in the report Agouron, ALZA, Amarillo, Anadys, Axys, BioMedicines, Biopharm Group, BioVex, Boehringer Ingelheim, Bristol Myers Squibb, Chiron, Corvas, Dimethaid, Dynavax Technologies, Eli Lilly, Enzo, Epimmune, Eurodiagnostica, Fumapharm, Genencor, GeneTrol, GenPhar, GlaxoSmithKline, Hawaii Biotech Group, Human Genome Sciences, ICN Pharm., Immusystems, Inhale Thera., Innogenetics, InterCell, InterMune, Lexicon Genetics, Maxim Pharmaceuticals, Medivir, Merck, Metaphore Pharmaceuticals, Oxo Chemie, Pepgen Corp., Pharming, Phogen, Roche, Schering-Plough, SciClone, Toray Industries, Triangle Pharmaceuticals, Tripep, Vernalis, Vertex, Viragen, XTL Biopharmaceuticals |
|
|||
|
About MarketResearch.com
|
||||